Market Research Logo

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

“Cancer/tumor profiling market is projected to grow at a CAGR of 10.5% during the forecast period (2019-2024).”
Cancer/tumor profiling market is projected to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. The increasing incidence of cancer across the globe and the rising use of biomarkers in tumor profiling are the primary growth drivers for this market. Additionally, the increase in cancer research & funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining the market growth.

“The next-generation sequencing (NGS) segment is expected to grow at the highest rate during the forecast period.”
Based on technology, cancer/tumor profiling market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The next-generation sequencing (NGS) segment is projected to witness the highest growth in cancer/tumor profiling market during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of a number of differentially expressed genes & genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of NGS technology in cancer/tumor profiling market.

“The lung cancer segment is expected to grow at the highest CAGR during the forecast period.”
Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing incidence of lung cancer worldwide and the growing need for early diagnosis are supporting the growth of this segment.

“The protein biomarkers segment is expected to grow at the highest CAGR during the forecast period.”
Based on biomarker type, cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. The protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase an enormous potential for directing personalized cancer therapy and treatment monitoring.

“The clinical applications segment is expected to grow at the highest rate during the forecast period.”
Based on applications, cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment is further sub-segmented into biomarker discovery and personalized medicine. On the other hand, the clinical applications segment is sub-segmented into diagnostics, prognostics, screening, and monitoring & treatment.

The clinical applications segment is expected to grow at the highest CAGR during the forecast period. With the increasing incidence rate of cancers across the globe and the rising availability of molecular profiling, and functional assessment of signaling pathways of advanced solid tumors, the use of tumor profiling techniques is gaining momentum for clinical practice.

“APAC is projected to witness the highest growth during the forecast period.”
Although North America is expected to account for the largest share of global cancer/tumor profiling market in 2018, APAC is expected to witness the highest CAGR during the forecast period. This is primarily due to the high incidence of cancer, growing proteomics & genomics research, rising research funding, increasing investments by pharmaceutical & biotechnology companies, and growing awareness about personalized therapeutics.

A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%
By Designation: C-level-35%, Director-level-25%, and Others-40%
By Region: North America-45%, Europe-30%, Asia Pacific-20%, Rest of the World-5%

The prominent players in cancer/tumor profiling market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Research Coverage:
The report analyzes the market for various cancer/tumor profiling technologies and their adoption pattern. It aims at estimating the market size and future growth potential of cancer/tumor profiling market and the different segments such as by technology, cancer type, biomarker type, and application. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios offered by the top players in cancer/tumor profiling market.
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in cancer/tumor profiling market.
Market Development: Comprehensive information on lucrative emerging regions.
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in global cancer/tumor profiling market.
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading players in cancer/tumor profiling market.


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
    • CURRENCY
    • STAKEHOLDERS
    • LIMITATIONS
  • RESEARCH METHODOLOGY
    • RESEARCH APPROACH
      • SECONDARY RESEARCH
      • PRIMARY RESEARCH
    • MARKET SIZE ESTIMATION
    • DATA TRIANGULATION APPROACH
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • CANCER/TUMOR PROFILING: MARKET OVERVIEW
    • CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2019-2024)
    • CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2019 VS. 2024)
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • MARKET DRIVERS
        • Table MARKET DRIVERS: IMPACT ANALYSIS
      • MARKET RESTRAINTS
        • Table MARKET RESTRAINTS: IMPACT ANALYSIS
      • MARKET OPPORTUNITIES
        • Table MARKET OPPORTUNITIES: IMPACT ANALYSIS
      • MARKET CHALLENGES
        • Table MARKET CHALLENGES: IMPACT ANALYSIS
  • INDUSTRY INSIGHTS
    • INTRODUCTION
    • INDUSTRY TRENDS
      • INTEGRATION OF OMICS DATA
      • ADVANCES IN LIQUID BIOPSY
      • ORGANOIDS FOR PERSONALIZED MEDICINE
  • CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
    • INTRODUCTION
      • Table CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
    • IMMUNOASSAYS
      • IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
        • Table CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2017-2024 (USD MILLION)
    • NEXT-GENERATION SEQUENCING
      • ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
        • Table CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017-2024 (USD MILLION)
    • POLYMERASE CHAIN REACTION
      • REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
        • Table CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017-2024 (USD MILLION)
    • IN SITU HYBRIDIZATION
      • FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
        • Table CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017-2024 (USD MILLION)
    • MICROARRAYS
      • MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
        • Table CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2017-2024 (USD MILLION)
    • MASS SPECTROMETRY
      • TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS
        • Table CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2017-2024 (USD MILLION)
    • OTHER TECHNOLOGIES
      • Table CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE
    • INTRODUCTION
      • Table CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
    • BREAST CANCER
      • BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
        • Table CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
    • LUNG CANCER
      • MOLECULAR CHARACTERIZATION OF TUMORS USING NGS HAS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
        • Table CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
    • COLORECTAL CANCER
      • IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
        • Table CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
    • PROSTATE CANCER
      • PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
        • Table CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
    • MELANOMA
      • RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
        • Table CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2017-2024 (USD MILLION)
    • OTHER CANCERS
      • Table CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE
    • INTRODUCTION
      • Table CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
    • GENETIC BIOMARKERS
      • GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
        • Table CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2017-2024 (USD MILLION)
    • PROTEIN BIOMARKERS
      • PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
        • Table CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2017-2024 (USD MILLION)
    • OTHER BIOMARKERS
      • Table CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • CANCER/TUMOR PROFILING MARKET, BY APPLICATION
    • INTRODUCTION
      • Table CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
    • RESEARCH APPLICATIONS
      • Table CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • BIOMARKER DISCOVERY
        • Table CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2017-2024 (USD MILLION)
      • PERSONALIZED MEDICINE
        • Table CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2017-2024 (USD MILLION)
    • CLINICAL APPLICATIONS
      • Table CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • DIAGNOSTICS
        • Table CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2017-2024 (USD MILLION)
      • PROGNOSTICS
        • Table CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2017-2024 (USD MILLION)
      • MONITORING & TREATMENT
        • Table CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2017-2024 (USD MILLION)
      • SCREENING
        • Table CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2017-2024 (USD MILLION)
  • CANCER/TUMOR PROFILING MARKET, BY REGION
    • INTRODUCTION
      • Table CANCER/TUMOR PROFILING MARKET, BY REGION, 2017-2024 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • Table NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • US
        • Table US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • CANADA
        • Table CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
    • EUROPE
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • Table EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • GERMANY
        • Table GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • UK
        • Table UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • FRANCE
        • Table FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • ITALY
        • Table ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • SPAIN
        • Table SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • REST OF EUROPE
        • Table ROE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table ROE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table ROE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table ROE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table ROE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
    • ASIA PACIFIC
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • Table ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • JAPAN
        • Table JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • CHINA
        • Table CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • INDIA
        • Table INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
      • REST OF ASIA PACIFIC
        • Table ROAPAC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table ROAPAC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table ROAPAC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table ROAPAC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table ROAPAC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
    • LATIN AMERICA
      • GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH
        • Table LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
    • MIDDLE EAST & AFRICA
      • GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH
        • Table MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2024 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • COMPETITIVE LEADERSHIP MAPPING
      • VISIONARY LEADERS
      • INNOVATORS
      • DYNAMIC DIFFERENTIATORS
      • EMERGING COMPANIES
    • COMPETITIVE SITUATION AND TRENDS
      • PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
        • Table PRODUCT LAUNCHES, 2016-2019
      • EXPANSIONS
        • Table EXPANSIONS, 2016-2019
      • ACQUISITIONS
        • Table ACQUISITIONS, 2016-2019
      • OTHER STRATEGIES
        • Table OTHER STRATEGIES, 2016-2019
  • COMPANY PROFILES
    • ILLUMINA, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • QIAGEN N.V.
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • NEOGENOMIC LABORATORIES, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • SYSMEX CORPORATION
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • HTG MOLECULAR DIAGNOSTICS, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • HELOMICS CORPORATION
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • GENOMIC HEALTH, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • CARIS LIFE SCIENCES
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • NANOSTRING TECHNOLOGIES, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • RIBOMED BIOTECHNOLOGIES, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND SERVICES OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • GUARDANT HEALTH, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • FOUNDATION MEDICINE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • MARKET SIZING & VALIDATION APPROACH
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report